About Us
Our Company
Our Team
Directors
Contact
Our Science
VAAST Platform
Mucosal Immunity
Platform Difference
Pipeline
COVID-19
Norovirus
Influenza
HPV
Publications
Investors
Careers
Vaxart Guiding Principles
Benefits
Open Positions
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
March 12, 2026
Vaxart to Host Upcoming Conference Calls
March 3, 2026
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
February 18, 2026
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
January 15, 2026
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
January 8, 2026
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
November 13, 2025
Vaxart to Host Upcoming Conference Calls
November 7, 2025
Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program
November 5, 2025
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
October 8, 2025
Vaxart Appoints W. Mark Watson as Lead Independent Director
September 17, 2025
1
2
3
4
Next Page
→
